Tech Support


This line is for technical support.
For General Enquiries please click General Contact

On-Demand Webinar

Overcoming Challenges in NAFLD/NASH Preclinical Modeling

NASH Day WebinarPresenter: Dr Guodong Zhang, Crown Bioscience

While the race for the first clinical NASH approval intensifies, preclinical research continues to be limited by multiple factors. There is no ideal preclinical NASH model, naturally recapitulating both the long term metabolic and liver fibrosis components of NASH, and existing clinical tests are not translatable to rodent models.

This means that selecting a preclinical NASH model usually results in choosing between fast and severe fibrosis without dysmetabolism, or an appropriate dysmetabolic background with only mild NASH. Using rodent models, the most common preclinical platform, also limits using clinically relevant techniques (e.g. MRI, ultrasound) to assess disease progression.

This webinar will offer new solutions to these preclinical challenges to optimize NAFLD/NASH research. Dr Guodong Zhang will explore a range of different NASH models and induction techniques, as well as alternative methods to evaluate liver disease progression.

Watch this Webinar to Learn:

  • How to select NASH preclinical models and induction methods to maximize your research goals

  • The pros and cons of common nutritional deficit diets, over-nutrition diets, and chemical induction methods to induce NASH

  • How next generation NASH models combine dysmetabolism and severe NASH for more translatable preclinical studies

  • Advantages and disadvantages of popular rodent strains and NHPs in NASH preclinical drug screening

  • Alternative methods for evaluating fatty liver disease progression in preclinical models, including pro-inflammatory panels and NHP non-invasive ultrasound

Who Should Watch:

  • Scientists looking to understand when and how to best utilize various animal models and induction methods for NAFLD/NASH

  • Drug developers interested in maximizing preclinical animal modeling for NAFLD/NASH therapeutics

  • Researchers looking to evaluate the vast array of preclinical models of NASH, including combined dysmetabolim and severe NASH models, and the pros and cons of each

Watch Now!

About The Presenter:

Dr Guodong Zhang, Crown BioscienceDr Guodong Zhang is the Director of Cardiovascular and Metabolic Disease division at Crown Bioscience. He specializes in the research and development of animal models of obesity, diabetes, dyslipidemia, NAFLD/NASH, and cardiovascular disease, with a focus on unique translatable models of metabolic disease in both rodents (the MS-NASH mouse and ZDSD rat) and NHPs (spontaneous diabetic cynomolgus macaques). Dr. Zhang holds a Ph.D. in Biomedical Engineering from Louisiana Tech University, and was previously the Head of Disease Models at Wincon TheraCells Biotechnologies Co., Ltd. where he was involved in preclinical research in non-human primates. Dr. Zhang has over 10 years of metabolic disease research experience, holds three patents in NHP and rodent animal models and has presented his work on numerous conferences and publications. He also served as the IACUC Chairperson for multiple years, supervising the ethical care and use of all studies involving laboratory animals.

Watch Now!

Your privacy is important to us.
We'll never share your information.